Efficacy and Safety of AK002 in Adult Patients with Active Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis: Primary Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial (ENIGMA Study)

(1) University of North Carolina at Chapel Hill,Chapel Hill,United States

(2) University of Utah School of Medicine,Salt Lake City,United States

(3) Mayo Clinic, Rochester,Rochester,United States

(4) University of Pennsylvania Perelman School of Medicine,Pennsylvania,United States

(5) Northwestern University School of Medicine,Chicago,United States

(6) Icahn School of Medicine at Mount Sinai,New York,United States

(7) Tufts Medical Center,Boston,United States

(8) University of Texas (UT) Southwestern,Dallas,United States

(9) Cincinnati Children's Hospital Medical Center,Cincinnati,United States

(10) National Institutes of Health / NIAID,Bethesda,United States

(11) Allakos,Redwood City,United States

(12) Northwestern University,Chicago,United States



This item was part of the Late breaking abstracts: From eosinophilic oesophagitis to novel obesity therapies (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019